Accessibility Menu
Ardelyx logo

Ardelyx(NASDAQ) ARDX

Market Cap$969.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-72%
5 Year+190%
1 Year-36%
1 Month-23%
Premium Feature
Moneyball Superscore
65/100
$3.90
-0.13%
-0.00Today
After hours$3.89-$0.01 (-0.26%)
Ardelyx last closing stock price
MetricPriceDate
Last closeUSD 3.892026-08-21
Ardelyx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.19%USD 4.062026-08-14
1 month-23.43%USD 5.082026-07-22
3 month-36.33%USD 6.112026-05-22
Year to date-33.28%USD 5.832025-12-31
1 year-36.33%USD 6.112025-08-21
3 year+10.83%USD 3.512023-08-22
5 year+190.3%USD 1.342021-08-20
Since inception-72.43%USD 14.112014-06-19

Ardelyx Financials at a Glance

Market Cap

$969.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$450.89M

Net Income (TTM)

-$55.70M

EPS (TTM)

-$0.23

P/E Ratio

-17.20

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$3.90

Volume

2,879,273.645

Open

$3.92

Previous Close

$3.89

Daily Range

$3.88 - $3.97

52-Week Range

$3.86 - $8.40

Estimated Earnings Date

Oct 29, 2026

ARDX News

SellAlert-Purple.png

Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction

Jonathan PoncianoJun 23, 2026
SellAlert-Red.png

Ardelyx President and CEO Sells 41,000 Shares for $243,000

Sarah SidlowApr 3, 2026
SellAlert-Blue.png

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Adé HennisMar 1, 2026
Foolcom-Featured.png

Ardelyx Q2 Revenue Jumps 33%

Motley Fool Markets TeamAug 5, 2025
GettyImages-1487838053-601x400-bf06395.jpg

Ardelyx Tops Estimates as Sales Surge

Motley Fool Markets TeamFeb 20, 2025
GettyImages-849227020-600x400-bf06395.jpg

Ardelyx Surpasses Q3 Revenue Estimates

Motley Fool Markets TeamOct 31, 2024
green arrow up stock chart

Why Ardelyx Stock Soared Today

Steve SymingtonOct 31, 2023
retired man undergoing chemotherapy cancer health sick

Why Ardelyx Stock Popped Today

Steve SymingtonOct 18, 2023
Page 1

ARDX: Motley Fool Moneyball Superscore

65

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ardelyx

Ardelyx, Inc. makes medicines for people with chronic stomach and kidney diseases. Its treatments help patients manage conditions that are often hard to control with standard care. The company focuses on turning its own scientific research into available drugs.

Help for Chronic Conditions

  • IBSRELA: Treatment for adults with Irritable Bowel Syndrome with Constipation; generated $86.2 million in product sales in the second quarter of 2026.
  • XPHOZAH: Therapy for high phosphorus levels in patients on dialysis; provided $31.9 million in product sales for the quarter ended June 30, 2026.
  • Tenapanor Expansion: Clinical program evaluating the lead drug for Chronic Idiopathic Constipation; expects to announce topline data in the second half of 2027.
  • Next-Generation Pipeline: Research into RDX10531, a therapy designed for better solubility and potency than current treatments.

Where Is Growth Coming From?

  • Initiated the Phase 3 ACCEL trial in Jan. 2026 to study tenapanor for chronic constipation.
  • Secured better borrowing terms through a Sixth Amendment to its loan agreement in April 2026.
  • Drew $50.0 million from a Term F Loan in June 2026 for general corporate purposes.
  • Maintained strategic partnerships with companies in Japan, China, and Canada to expand the reach of its therapies.

Science-Driven Solutions

Ardelyx identifies and develops its own drug candidates rather than licensing them from other firms. This internal discovery process allows the company to maintain full control over its primary gastrointestinal and cardiorenal therapies.

Gains in Product Sales

  • Total revenue reached $120.9 million for the quarter ended June 30, 2026, a 24% increase year over year.
  • Product sales grew to $211.5 million for the six months ended June 30, 2026, up 34% year over year.
  • Research and development spending rose 67% to $26.1 million during the second quarter of 2026.
  • Selling, general, and administrative expenses were $101.4 million in the second quarter of 2026, up 21% year over year.
  • Cash, cash equivalents, and short-term investments totaled $281.8 million as of June 30, 2026.

Moving to a Commercial Future

Ardelyx has transitioned from a research-focused organization into a commercial-stage firm with two marketed products. Its evolution focuses on expanding the use of current therapies while investing in a specialized clinical pipeline.

AI Generated • Aug 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

489

CEO

Mike Raab

Website

www.ardelyx.com

Headquarters

Waltham, MA 02451, US

ARDX Financials

Key Financial Metrics (TTM)

Gross Margin

93.96%

Operating Margin

-7.86%

Net Income Margin

-12.35%

Return on Equity

-36.00%

Return on Capital

-10.82%

Return on Assets

-9.67%

Earnings Yield

-5.81%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$969.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

249.19M

Volume

2.88M

Avg. Volume

4.12M

Financials (TTM)

Gross Profit

$423.67M

Operating Income

-$35.45M

EBITDA

-$23.78M

Operating Cash Flow

-$17.32M

Capital Expenditure

-$599.00K

Free Cash Flow

-$17.92M

Cash & ST Invst.

$281.83M

Total Debt

$256.19M

Ardelyx Performance Analysis

Ardelyx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 52,158,000416.6%
20232023-12-31USD 124,456,000138.6%
20242024-12-31USD 333,615,000168.1%
20252025-12-31USD 407,320,00022.1%
Ardelyx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3013.0%
Q42025-12-3113.5%
Q12026-03-31-24.6%
Q22026-06-3027.9%
Ardelyx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.42-72.1%
20232023-12-31USD -0.30-28.9%
20242024-12-31USD -0.17-44.8%
20252025-12-31USD -0.2653.6%
Ardelyx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3095.0%
Q42025-12-3157.5%
Q12026-03-31-8723.5%
Q22026-06-3053.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$120.88M

+23.8%

Gross Profit

$115.12M

+36.0%

Gross Margin

95.24%

N/A

Market Cap

$969.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.98M

N/A

Employees

489

N/A

Net Income

-$16.72M

+12.4%

EBITDA

-$10.14M

+14.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$281.83M

+18.2%

Total Debt

$256.19M

+24.0%

Accounts Receivable

$100.35M

+60.4%

Inventory

$25.86M

+16.1%

Long Term Debt

$254.65M

+23.9%

Short Term Debt

$1.55M

+30.7%

Return on Assets

-9.67%

N/A

Return on Invested Capital

-7.99%

N/A

Free Cash Flow

-$6.41M

+75.3%

Operating Cash Flow

-$6.40M

+74.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
WVEWave Life Sciences Ltd.
$5.29+0.76%
UPBUpstream Bio, Inc.
$6.97+1.75%
MAZEMaze Therapeutics, Inc.
$29.43+1.73%
NTLAIntellia Therapeutics, Inc.
$12.84+3.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About ARDX

What is the current price of Ardelyx?

Ardelyx is trading at $3.89 per share.

What is the 52-week range for Ardelyx?

Over the past 52 weeks, Ardelyx has traded between $3.86 and $8.40.

How much debt does Ardelyx have?

As of the most recent reporting period, Ardelyx reported total debt of $256.19M.

How much cash does Ardelyx have on hand?

Ardelyx reported $97.19M in cash and cash equivalents in its most recent financial results.

What is Ardelyx’s dividend yield?

Ardelyx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services